secwatch.observer — SEC 8-K summary
======================================

Issuer:     PALVELLA THERAPEUTICS, INC. (PVLA)
CIK:        0001583648
Form:       8-K
Filed at:   2026-05-20T20:35:15+00:00
Accession:  0001193125-26-232717
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Palvella Phase 3 SELVA: 100% of children responded; NDA filing on track for H2 2026
--------------------------------------------------------------------------------

- Phase 3 SELVA: 100% of 13 children (6-11 yrs) rated 'Much Improved' or better on mLM-IGA at Week 24 (mean +2.46, p<0.001).
- 87% (20/23) with baseline leaking/bleeding showed 'Much Improved' or better on leaking/bleeding scale at Week 24 (mean +2.48).
- Blinded review: pre-treatment stability, then 48% max improvement after 24 weeks (mean mLM-MCSS from 9.9 to 6.6).
- Phase 2 TOIVA: stat sig improvements in cVM-MCSS Height (mean -1.50) and Appearance (mean -1.43) at Week 24 (p<0.001).
- NDA submission for microcystic LMs planned H2 2026; Phase 3 for cutaneous VMs starts H2 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1583648/000119312526232717/0001193125-26-232717-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1583648/000119312526232717/pvla-20260520.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-232717

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer